Seven Grand Managers LLC Buys Shares of 35,000 Disc Medicine, Inc. $IRON

Key Points

• Seven Grand Managers LLC opened a new position in Disc Medicine, buying 35,000 shares worth about $2.78 million in the fourth quarter.
• Institutional ownership remains heavy, with several funds adding shares and 83.7% of the stock now held by institutional investors and hedge funds.
• Analysts are mostly bullish, with a Moderate Buy consensus and an average target price of $105.30, though Disc Medicine recently reported a quarterly EPS loss that slightly missed estimates.

Seven Grand Managers LLC bought a new stake in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 35,000 shares of the company's stock, valued at approximately $2,779,000. Seven Grand Managers LLC owned approximately 0.09% of Disc Medicine as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Geode Capital Management LLC raised its position in shares of Disc Medicine by 9.0% in the 4th quarter. Geode Capital Management LLC now owns 684,958 shares of the company's stock valued at $54,402,000 after purchasing an additional 56,807 shares in the last quarter. Eagle Health Investments LP acquired a new position in shares of Disc Medicine in the 4th quarter valued at approximately $2,152,000. Atle Fund Management AB raised its position in shares of Disc Medicine by 5.0% in the 4th quarter. Atle Fund Management AB now owns 47,967 shares of the company's stock valued at $3,809,000 after purchasing an additional 2,277 shares in the last quarter. TimesSquare Capital Management LLC raised its position in shares of Disc Medicine by 3.1% in the 4th quarter. TimesSquare Capital Management LLC now owns 187,777 shares of the company's stock valued at $14,911,000 after purchasing an additional 5,607 shares in the last quarter. Finally, Profund Advisors LLC raised its position in shares of Disc Medicine by 66.0% in the 4th quarter. Profund Advisors LLC now owns 13,478 shares of the company's stock valued at $1,070,000 after purchasing an additional 5,360 shares in the last quarter. 83.70% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

IRON has been the topic of a number of recent analyst reports. Morgan Stanley upped their target price on Disc Medicine from $75.00 to $80.00 and gave the company an "overweight" rating in a research report on Thursday, May 14th. Truist Financial cut their target price on Disc Medicine from $114.00 to $83.00 and set a "buy" rating on the stock in a research report on Friday, February 27th. BMO Capital Markets cut their target price on Disc Medicine from $120.00 to $100.00 and set an "outperform" rating on the stock in a research report on Tuesday, February 17th. Wells Fargo & Company upped their target price on Disc Medicine from $78.00 to $79.00 and gave the company an "overweight" rating in a research report on Monday, March 2nd. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Disc Medicine in a research report on Monday, April 20th. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $105.30.

Disc Medicine Stock Performance

IRON stock opened at $69.76 on Thursday. The company has a current ratio of 24.00, a quick ratio of 24.00 and a debt-to-equity ratio of 0.04. The firm has a market cap of $2.66 billion, a P/E ratio of -10.54 and a beta of 0.93. Disc Medicine, Inc. has a 12-month low of $40.00 and a 12-month high of $99.50. The stock's 50 day simple moving average is $66.22 and its 200 day simple moving average is $74.09.

Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.62) by ($0.03). As a group, equities research analysts predict that Disc Medicine, Inc. will post -6.78 EPS for the current year.

Insider Activity at Disc Medicine

In related news, CFO Jean M. Franchi sold 6,257 shares of the company's stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $69.24, for a total transaction of $433,234.68. Following the sale, the chief financial officer directly owned 64,333 shares of the company's stock, valued at approximately $4,454,416.92. This represents a 8.86% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider William Jacob Savage sold 5,731 shares of the company's stock in a transaction that occurred on Monday, April 13th. The shares were sold at an average price of $66.38, for a total value of $380,423.78. Following the sale, the insider directly owned 79,480 shares in the company, valued at approximately $5,275,882.40. This represents a 6.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 19,766 shares of company stock worth $1,327,321. Corporate insiders own 3.76% of the company's stock.

Disc Medicine Profile

Disc Medicine, Inc NASDAQ: IRON is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.